Pfizer Inc. (PFE) Announces Positive Results From its Phase 3 HER2CLIMB-05 Trial

​Pfizer Inc. (NYSE:PFE) is one of the Best Growth Stocks Under $25 to Buy Right Now. On October 14, Pfizer Inc. (NYSE:PFE) announced positive results from its Phase 3 HER2CLIMB-05 trial.

​The trial tested the kinase inhibitor TUKYSA with first-line combination therapy for patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer. The trial met its endpoints, demonstrating significant improvement in progression-free survival against the placebo.

​Management noted that HER2+ breast cancer is a challenging type of cancer with many patients experiencing disease progression despite effective treatments. The results from this trial suggest that HER2CLIMB-05, along with TUKYSA, has the ability to stop disease progression, while maintaining a healthy safety profile.

​Pfizer Inc. (NYSE:PFE) is a global biopharmaceutical company focused on discovering, developing, manufacturing, and marketing medicines.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.